![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/10\/20261021_Roivant_Therapeutic_Indications-768x512.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Roivant; Priovant Therapeutics<\/p>\n Event Type<\/strong><\/p>\n Phase 3 Topline Results (CLARITY-1 and CLARITY-2)<\/p>\n Modality<\/strong><\/p>\n Small molecule; oral TYK2\/JAK1 inhibitor<\/p>\n Asset<\/strong><\/p>\n Brepocitinib<\/p>\n Target<\/strong><\/p>\n TYK2; JAK1<\/p>\n Disease Area<\/strong><\/p>\n Noninfectious uveitis<\/p>\n Brepocitinib met the primary and multiplicity-controlled secondary endpoints in both CLARITY phase 3 studies of noninfectious uveitis. The independent replication and clinically relevant steroid taper make this a strong late-stage immunology signal; full safety and durability review remains essential.<\/p>\n Across 371 randomized patients, both double-masked trials compared oral brepocitinib 45 mg daily with placebo for 48 weeks while all participants completed a mandated eight-week prednisone taper. Treatment-failure hazard ratios were 0.27 and 0.22 (both p<0.0001). Week-48 failure was 35.4% versus 78.7% in CLARITY-1 and 32.4% versus 77.8% in CLARITY-2. Pooled steroid-free quiescence was 62% versus 20%; macular-edema resolution among affected eyes was 42% versus 4.8%. Priovant plans an sNDA in the first half of 2027.<\/p>\n The design separates inflammation control from chronic corticosteroid maintenance. Concordant treatment-failure, quiescence, retinal anatomy and patient-reported vision findings reduce the likelihood that a single endpoint drove the result. TYK2\/JAK1 inhibition may interrupt multiple cytokine pathways relevant across uveitis etiologies, though the release does not establish differential efficacy by subtype.<\/p>\n The counterinterpretation is that placebo under an aggressive steroid taper may make the absolute difference appear larger than a comparison against contemporary active immunomodulation. No head-to-head trial establishes superiority over adalimumab or other systemic options. JAK-class boxed warnings, infection and thrombotic risk, exposure duration and subgroup consistency require regulatory scrutiny; the company reported no new safety signal and 3% adverse-event discontinuation, but granular adverse-event tables are not yet available.<\/p>\n Brepocitinib is an oral TYK2\/JAK1 inhibitor. Priovant is a Roivant company; the molecule is approved in adult dermatomyositis but not uveitis. Noninfectious uveitis is immune-mediated ocular inflammation that can cause irreversible visual loss.<\/p>\n Inference: replicated steroid-sparing efficacy creates a credible new systemic option for sight-threatening inflammation. Comparative positioning remains unresolved until active-control evidence and detailed safety data appear.<\/p>\n Signal Importance: 5 of 5. Signal Direction: Positive, conditional. Confidence in Facts: High. Confidence in Interpretation: Moderate\u2013High. The direction score describes the evidence at this stage. It does not imply clinical approval, treatment readiness or commercial outcome.<\/p>\n","protected":false},"excerpt":{"rendered":" Brepocitinib met the primary and multiplicity-controlled secondary endpoints in both CLARITY phase 3 studies of noninfectious uveitis. The independent replication and clinically relevant steroid taper make this a strong late-stage immunology signal; full safety…<\/p>\n","protected":false},"author":1,"featured_media":3820,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[452,1158,1107,1157,1156],"class_list":["post-3818","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-brepocitinib","tag-noninfectious-uveitis","tag-phase-3","tag-priovant","tag-roivant"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3818"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3818\/revisions"}],"predecessor-version":[{"id":3837,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3818\/revisions\/3837"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3820"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n